Albany Molecular Research Inc. (NASDAQ:AMRI)’s share price fell 0.7% during trading on Friday . The company traded as low as $14.53 and last traded at $14.60, with a volume of 68,690 shares. The stock had previously closed at $14.71.

Separately, Morgan Stanley reissued a “buy” rating and set a $17.00 price target on shares of Albany Molecular Research in a research note on Friday, August 5th.

The stock has a 50 day moving average price of $14.65 and a 200 day moving average price of $14.61. The firm’s market capitalization is $505.85 million.

Albany Molecular Research (NASDAQ:AMRI) last released its quarterly earnings results on Thursday, August 4th. The company reported $0.36 earnings per share for the quarter, topping analysts’ consensus estimates of $0.32 by $0.04. The business earned $116.50 million during the quarter, compared to analyst estimates of $123.10 million. On average, equities research analysts anticipate that Albany Molecular Research Inc. will post $1.09 earnings per share for the current fiscal year.

Albany Molecular Research, Inc is a global contract research and manufacturing company. The Company provides drug discovery, development, and manufacturing services. The Company operates through three segments: Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API) and Drug Product Manufacturing (DPM).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.